SDZNY (Sandoz Group AG) Momentum Rank : 0 (As of Dec. 12, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Momentum Rank?

Sandoz Group AG has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Sandoz Group AG Momentum Rank Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZz:UK 0SAN:UK D8Y0:Germany SDZ:Switzerland

Address

Forum 1, Novartis Campus, Basel, CHE, CH-4056

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Sandoz Group AG Headlines

From GuruFocus

Sandoz Group AG (SDZNY) (Q2 2024) Earnings Call Transcript Highlights: Strong Biosimilars Growth and Raised Sales Guidance

By GuruFocus Research • 08-09-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Half Year 2024 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 08-09-2024